Table 1.

Characteristics of participants. Age is described as mean and standard deviation

No.	Study	Group	Total number of randomized patients	Age	TBSA (%) of patients to be included	Country	Socio-demographics
1	Williams 2011 [29]	Propranolol	125	7 (5)	Burns >30%	USA	Not described
		Standard care	215	8 (5)
2	W Norbury 2007 [28]	Propranolol	33	Not described	Burns >40%	USA	Not described
		Standard care	33	Not described
3	Wurzer 2015 [30]	Propranolol	43	Not described	Burns >30%	USA	Not described
		Standard care	39
4	Ali 2014 [21]	Propranolol	21	Not described	Burns >30%	USA	Not described
		Standard care	21
5	Komak 2012 [26]	Propranolol	29	Not described	Burns >40%	USA	Not described
		Standard care	35
6	Ali 2015 [22]	Propranolol	35	41 (14)	Burns >30%	USA	Not described
		Standard care	34	38 (16)
7	Herndon 2012 [24]	Propranolol	90	7 (5)	Burns >30%	USA	Majority of participants were Hispanic: 97% in the control group and 91% in the propranolol group
		Standard care	89	7 (5)
8	Akbar Mohammadi 2009 [27]	Propranolol	37	27.21 (9.73)	Burns 20–50%	Iran	Not described
		Standard care	42	24.54 (12.06)
9	Jeschke 2007 [25]	Propranolol	102	7.2 (0.6)	Burns >40%	USA	Not described
		Standard care	143	7.8 (0.4)
10	Herndon 2001 [23]	Propranolol	12	6.6 (1.5)	Burns >40%	USA	Not described
		Standard care	12	7.8 (1.4)